In vivo evidence of functional OATP2B1 activity in human skeletal muscle using [11C]erlotinib PET

Résumé fourni par la source

• In vivo measurement of OATP2B1 activity in human skeletal muscle • Use of [ 11 C]erlotinib as an OATP2B1-specific PET probe substrate • Oral erlotinib pre-treatment partially saturates muscular OATP2B1 transport • Findings suggest a role of OATP2B1 in muscle accumulation and toxicity of substrate drugs (e.g., statins) Organic anion-transporting polypeptide 2B1 (OATP2B1/SLCO2B1) is an uptake transporter expressed in the liver and in several extrahepatic tissues, including skeletal muscle. Muscular OATP2B1 is thought to facilitate intracellular accumulation of statins, potentially contributing to statin-induced myotoxicity. To investigate functional OATP2B1 activity in vivo in human skeletal muscle, we performed positron emission tomography (PET) with the radiolabelled OATP2B1 substrate [ 11 C]erlotinib. Nine healthy male volunteers (age: 31 ± 9 years) underwent two dynamic 60-min PET scans of the head with concurrent arterial blood sampling following intravenous injection of a microdose of [ 11 C]erlotinib (< 10 µg). The first scan was performed without any pharmacological pre-treatment (baseline scan), whereas the second scan was performed after pre-treatment with a single oral dose of unlabelled erlotinib (650 mg), administered 3.0 ± 0.1 h before the start of the PET scan. Volumes of interest (VOIs) were manually delineated for the right and left temporal muscle surrounding the skull on co-registered PET/magnetic resonance imaging (MRI) data and averaged to generate a global temporal muscle VOI. Time-activity curves for temporal muscle and arterial plasma were analysed using a 1-tissue-2-rate constant (1T2K) compartment model and Logan graphical analysis to estimate the total volume of distribution ( V T ) of [ 11 C]erlotinib (reflecting the steady-state muscle-to-plasma concentration ratio), as well as the rate constants for transfer of [ 11 C]erlotinib from plasma to muscle ( K 1 ) and from muscle to plasma ( k 2 ). Both Logan analysis and the 1T2K model demonstrated a significant reduction in V T after erlotinib pre-treatment compared with baseline ( V T Logan : baseline: 0.85 ± 0.11 mL/cm 3 , erlotinib: 0.70 ± 0.08 mL/cm 3 , −18 ± 8%, p = 0.00047; V T 1T2K : baseline: 0.83 ± 0.11 mL/cm 3 , erlotinib: 0.67 ± 0.07 mL/cm 3 , −18 ± 7%, p = 0.00033). K 1 showed a trend toward reduction after erlotinib pre-treatment without reaching statistical significance, whereas k 2 remained unchanged. Our findings demonstrate saturable distribution of [¹¹C]erlotinib to human skeletal muscle, consistent with functional OATP2B1 activity. These results support a mechanistic role for muscular OATP2B1 in statin-induced myotoxicity and highlight its potential broader relevance for the safety and pharmacology of other OATP2B1 substrate drugs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.